Akèy › Limfom Difize Gwo Selil B › Idaho
Etid klinik pou Limfom Difize Gwo Selil B nan Idaho
4 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Idaho.
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- Kootenai Clinic Cancer Services - Post Falls, Post Falls
- Kootenai Clinic Cancer Services - Sandpoint, Sandpoint
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06649812A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Beacon Cancer Care ( Site 0142), Post Falls
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- St Luke?s Cancer Institute, Boise
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06806033Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Saint Luke's Cancer Institute - Boise, Boise
- Saint Luke's Cancer Institute - Fruitland, Fruitland
- Saint Luke's Cancer Institute - Meridian, Meridian
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.